Re‐biopsy and liquid biopsy for patients with non‐small cell lung cancer after EGFR‐tyrosine kinase inhibitor failure

Re‐biopsy and liquid biopsy for patients with non‐small cell lung cancer after EGFR‐tyrosine kinase inhibitor failure

Background Re‐biopsy is important for exploring resistance mechanisms, especially for non‐small cell lung cancer (NSCLC) patients who develop resistance to EGFR‐tyrosine kinase inhibitors (TKIs). Liquid biopsy using circulating tumor DNA has come into use for this purpose. This retrospective study i...

Full description

Bibliographic Details
Main Authors: Juan Zhou, Chao Zhao, Jing Zhao, Qi Wang, Xiangling Chu, Jiayu Li, Fei Zhou, Shengxiang Ren, Xuefei Li, Chunxia Su, Caicun Zhou
Format: Article
Language:English
Published: Wiley 2019-04-01
Series:Thoracic Cancer
Subjects:
EGFR‐TKI resistance
liquid biopsy
non‐small cell lung cancer
re‐biopsy
Online Access:https://doi.org/10.1111/1759-7714.13035

Internet

https://doi.org/10.1111/1759-7714.13035

Similar Items